R&D-based pharmaceutical industry’s innovative partnerships to meet urgent global supply needs
This report highlights a select few collaborations with IFPMA companies, and details the innovative methods in which these collaborations are working to meet urgent global supply needs.
IFPMA member companies are at the forefront of the global effort to develop a safe
and effective COVID-19 vaccine and scale up manufacturing to ensure equitable
access to people around the world. In less than a year, several vaccines candidates
have been approved or are in advanced Phase III clinical trials with encouraging
results. An impressive and unprecedented manufacturing scale-up is also taking
place.
Downloads
Related news and resources
IFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi
On 1 March, at the end of the 13th WTO Ministerial Conference, IFPMA issued a statement.
Read moreFebruary 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
WTO Ministerial Conference in Abu Dhabi is an opportunity to strengthen trade and health agenda
On 23 February, ahead of the 13th WTO Ministerial Conference, IFPMA and member associations from 10 countries issued a joint statement calling on trade ministers to commit to a comprehensive trade and health agenda that will strengthen the innovation ecosystem, remove trade barriers, promote trade facilitation, strengthen regulatory systems, and address under-resourced healthcare infrastructure.
Read more